Trends in Neuro Device Investing

Transcription

1 Trends in Neuro Device Investing Advances in Neurology Drive New Activity MARCH 2018

2 Neuro Devices: A Highly Active Area in Medtech Neuro devices are medical devices used to diagnose and treat neurological diseases as well as non-neuro diseases in which the therapeutic effect is mediated through the nervous system. 1 The report s purpose is to highlight some of the leading private companies and investors in the space, the diseases they are targeting and the technologies they are developing. Note that this report is limited to private financings 2 of $1M+ between 2016 and 2017 and excludes structural treatments for pain (e.g., spinal fusion), in vitro diagnostics, regenerative medicine, non-medical solutions and joint ventures between large public companies. Investment activity is being fueled by: Significant unmet needs in neurological and psychiatric diseases Rapidly expanding knowledge of the nervous system and its broader influence on physiology The need to perform more timely interventions that mitigate the effects of diseases such as stroke Report Highlights: Financings increased by over 40 percent and invested equity grew by over 50 percent from 2016 to Significant early-stage investment took place, with 16 Seed and Series A financings raising more than $10M each, spanning all relevant disease areas. Nervous system diseases, including pain, movement disorders and epilepsy, among others, represented the largest disease focus for neuro devices, capturing 40 to 45 percent of financings in 2016 and Neuromodulation, or the direct stimulation of the nervous system, represented nearly 70 percent of the total invested equity in neuro devices. 1. Relevant disease areas have been selected and grouped according to ICD The sample includes 107 financings and 94 companies. Trends in Neuro Device Investing

3 Table of Contents Neuro Device Financings by Disease Focus 4 Neuro Device Financings by Modality 7 A Deeper Dive into Modalities 9 About the Authors 16 Trends in Neuro Device Investing

4 Neuro Device Financings by Disease Focus Trends in Neuro Device Investing

5 Private Company Investment Exceeds $1B in 2017 Neuro device companies raising rounds in 2016 and 2017 are grouped by lead program/device according to disease focus. Venture Investment in Neuro Devices: Number of Financings Invested Equity $749M $1,152M $10M+ Rounds: Nervous System 2 Pain Sleep Disease Area Invested Equity 1 Financing Count by Series Nervous System Neurovascular $962M $163M Paralysis/Rehabilitation Brain Tumors 3 Non-Neuro $373M 5 9 Movement Disorders Psychiatric Traumatic Brain Injury $204M $44M Neurocognitive Epilepsy Research/ Platform 4 $156M Companies focused on treating nervous system diseases represented 40 to 45 percent of financings in both 2016 and Invested equity in the same category increased from 45 percent in 2016 to 55 percent of the total invested equity in Total invested equity in 2016 and Stimwave (Pain), Invicta Medical (Sleep), Synergia Medical (Epilepsy), raised a $50M Series C, a $21M Series B and a $10M Series A round respectively in early Brain tumors have been grouped into nervous system diseases; ICD-10 classifieds neoplasms of the eye, brain and central nervous system separately. 4. Research/Platform includes companies that have not disclosed a clinical indication. Trends in Neuro Device Investing Sources: Pitchbook, CB Insights, SVB analysis

6 Strong Interest from Investors Across All Series A broad distribution of financings has supported development at all stages. Non-neuro drew significant interest, with the majority of dollars flowing to a few mid and late rounds. Venture Investment in Neuro Devices: Seed Series A Series B C Series D+ Number of Financings Invested Equity $575M $606M $720M $10M+ Rounds: Non-Neuro Hypertension Gastrointestinal Disease Area Invested Equity 1 Financing Count by Series (Series E: $20M) (Series C: $10M) (Series D: $12M) Nervous System $962M Heart Failure Metabolic Neurovascular 2 $163M 15 5 Non-Neuro 3 $373M (Series B: $23M) (Series G: $113M) (Series C: $65M) Psychiatric $204M Renal/Urinary 4 Inflammation Traumatic Brain Injury $44M Research/ Platform $156M 5 1 Seed Series A Series B C Series D+ (Series B: $35M) (Series C: $35M) (Series D: $30M) Sixteen Seed and Series A financings spanning all disease areas were $10M+ rounds, with the majority of these companies receiving their first venture capital (VC) investment. Four were research/platform companies, developing foundational technologies that will propel the next generation of neuro devices. 1. Total invested equity in all series. 2. Neurovascular does not include embolic protection technologies. 3. Non-neuro includes technologies that treat non-neurological diseases/disorders in which the therapeutic effect is mediated through the nervous system. 4. NeuSpera (overactive bladder) raised a $26M Series B round in early Trends in Neuro Device Investing Sources: PitchBook, CB Insights, SVB analysis

7 Neuro Device Financings by Modality Trends in Neuro Device Investing

8 Investment Increases for All Modalities Software-Based and imaging & monitoring neuro devices begin to attract VC attention. Venture Investment in Neuro Devices: Modality Financing Count by Series Series D+ Series B C Seed Series A Invested Equity 2 Venture Age 3 (Median) Financing Count by Disease Focus Nervous System Neurovascular Non-Neuro Psychiatric Traumatic Brain Injury Research/Platform Software-Based $178M $105M Imaging & Monitoring Device $149M $119M Therapeutic Device $528M $963M 1.0 Years 1.3 Years 3.7 Years Software-based solutions are dominated by early-series rounds and total invested equity is overwhelmingly driven by a few high performers. Furthermore, VC involvement in this modality is relatively recent. Financings increased modestly for imaging and monitoring devices but invested equity more than doubled when excluding MindMaze s $100M 2016 round. Surprisingly, despite this increase in invested equity, the distribution shifted to earlier rounds. Therapeutic devices are a more mature category with more than half of the invested equity going to laterseries rounds. That s not to say that early financing activity is anemic; Kernel, GTX medical and Neuralink raised over $167M combined in 2016 and Software-based does not include solutions whose function is primarily to connect patient and care provider. 2. Total invested equity in all series; 2016 software-based and imaging & monitoring device financings both include MindMaze s $100M Series A round. 3. Time from first VC investment to latest round. Trends in Neuro Device Investing Sources: PitchBook, CB Insights, SVB analysis

9 A Deeper Dive into Modalities Trends in Neuro Device Investing

10 Big Pharma Backs Software-Based Solutions Financings in software-based solutions are dominated by a few companies that are defining the category. Venture Investment in Software-Based Solutions: Round Group by Size Less Than $10M $10M+ $10M+ Rounds (Series A: $14M) Invested Equity 1 $34M $248M (Series B: $42M) Financing Count by Stage 2 $2M $4M Yrs. 1.5 Yrs. $26M $24M Yrs. 3.3 Yrs. (Series A: $100M) 4 (Series A: $20M) (Series B: $50M) Development Stage (Series A: $12M) Commercial Round Size (Median) Venture Age (Median) (Series A: $10M) Leading developers of softwarebased solutions are raising very large professionally led rounds in both development and commercial stages. These investments are focused on validating the modality s ability to treat neurological and psychiatric diseases. Despite the relatively low safety risk of these technologies, leading companies are conducting extensive clinical trials and seeking approved/cleared indications to achieve general acceptance of their therapeutic benefit. Active Tech Investors Active Life Sciences Investors With significant unmet needs in neurological and psychiatric diseases, combined with a short time to market, this new therapeutic approach should continue to attract the attention of high-profile investors and big pharma. 1. Total invested equity in all stages. 2. For sample sizes less than 5, round size and venture age figures represent means; MindMaze has not been included in the round size statistic. 3. Pear Therapeutics raised a development stage round in 2016 and a commercial round in Trends in Neuro Device Investing Sources: PitchBook, CB Insights, SVB analysis

11 Early Rounds Boost Imaging & Monitoring Six Series A rounds account for over half of the total invested equity in imaging & monitoring. Venture Investment in Imaging & Monitoring Devices: Year Invested Equity 1 by Stage Financing Count $149M $119M $10M+ Rounds: 2016 (Series A: $10M) $8M Yrs. Round Size (Median) $6M $16M Yrs. 2.2 Yrs. (Series A: $13M) Development Stage $10M+ Rounds: 2017 (Series A: $11M) FDA Cleared/Approved Venture Age (Median) (Series A: $15M) Despite ongoing reimbursement challenges facing nontherapeutic medical devices, a handful of imaging and monitoring device companies are raising healthy rounds. Over 65 percent of the invested equity in 2016 came from MindMaze s $100M Series A round. When excluding that round, the majority of the increase from 2016 to 2017 was driven by four Series A rounds (Ceribell, Alzeca Biosciences, Neural Analytics, and Bioserenity). (Series A: $100M) Invasive Non-Invasive (Series B: $10M) Disease Focus by Form Factor Research/ Platform Neurovascular (Series D: $16M) Nervous System (Series B: $20M) Traumatic Brain Injury (Series A: $18M) Psychiatric On average, imaging & monitoring companies are gaining regulatory clearance/approval in one to two years after receiving their first VC investment, and total invested equity prior to commercialization tends to be less than $10M. 1. Total invested equity in all stages. Sources: PitchBook, CB Insights, SVB analysis Trends in Neuro Device Investing

12 Neuromodulation Dominates Therapeutic Devices Neuromodulation technologies represent over 70 percent of financings in therapeutic neuro devices and nearly 90 percent of the invested equity. $10M+ Rounds: Therapeutic Devices ( ) Nervous System Research/ Platform Psychiatric Non-Neuro Nervous System Neurovascular Disease Area Therapeutic Modality Neuromodulation Surgical Tools 2 Structural Repair 3 1. Numbers represent the total number of financings in each group. 2. Surgical tools includes devices used during a therapeutic procedure that are not left in the patient. 3. Structural repair includes implants who s therapeutic effect is achieved by occluding, opening, or otherwise supporting tissue. Sources: PitchBook, CB Insights, SVB analysis Trends in Neuro Device Investing

13 Neuromodulation Draws Broad Investor Interest Development cycles in neuromodulation can exceed 10 years, putting pressure on later-series rounds. Venture Investment in Neuromodulation Devices: Form Financing Count Factor Invested Equity 1 by Stage Invasive Noninvasive Most Active 2 $902M $383M Financial Investors Development Stage $5M $15M Yrs Yrs. FDA Cleared/Approved Round Size (Median) $18M $36M Yrs Yrs. Venture Age (Median) 3 More mature neuromodulation companies have historically been highly capital intensive and characterized by long development cycles. Nonetheless, this category continues to receive attention from high profile VCs and medical device corporates. Interestingly, FDA cleared/approved noninvasive and invasive companies have a similar venture age even though the noninvasive companies have been on the market for a lot longer on average (8.5 years for noninvasive versus 3.9 years for invasive). Most Active Corporate Investors Comment Active Biopharma Investors This confirms the challenges faced by first-generation noninvasive technologies, but recent VC interest in early-stage noninvasive companies such as Cala Health, Invicta Medical, and NeuraLace holds promise for the category. 1. Total invested equity in all stages. 2. Most Active Investors have invested in at least two neuromodulation companies from the sample in this report. 3. Action Potential Venture Capital is GSK s independently managed VC fund focused specifically on bioelectronics. Sources: PitchBook, CB Insights, SVB analysis Trends in Neuro Device Investing

14 Pre-Money Valuations 1 in Neuromodulation Healthy step-ups are common for early and mid-series rounds; however as with medical devices in general, step-ups become far more difficult at later-series rounds in the absence of solid commercial traction. Median Pre-Money 2 9 Total # of financings by series 2 $26M $42M $80M $11M Seed Series A Series B Series C Series D+ Round Size (Median) Prior Invested Equity (Median) Venture Age (Median) Comment $7M $20M $34M $25M $0M $10M $29M $95M 0 Yrs. 1.9 Yrs. 5.0 Yrs Yrs. 1. Pre-money valuation data is based on SVB proprietary data and publicly available information and represents slightly more than half of the publicly disclosed financings that have occurred in 2016 and Pre-money statistics: N=28 financings, 27 companies. 3. For sample sizes less than 5, pre-money valuations, round size, prior invested equity, and venture age figures represent means. Sources: PitchBook, CB Insights, SVB analysis Trends in Neuro Device Investing

15 Enabling Tech Sets the Stage for Future Growth Development of foundational technologies may lead to dramatic performance improvements and new applications for neuro devices. Novel Reading Technologies (Seed: $2M) Novel Neural Interfaces & Materials (Series A: $10M) Novel Powering Technologies Future bioelectronic medicines will contain closedloop feedback, advanced signal processing, and novel wireless powering to enable a new class of therapies that compete with earlier-line drugs and open entirely new markets. Minimally invasive devices with the ability to titrate dosing automatically and resolve the compliance challenges of drugs are becoming a reality. Juan-Pablo Mas & Imran Eba, Action Potential Venture Capital 1 (Series B: $7M) (Series A: $10M) (Series A: $9M) Closed Loop Systems (Series A: $100M) (Series A: $27M) (Series A: $5M) (Series A: $40M) "Bioelectronics represents a new and exciting era in medicine, in which we will be addressing brain disease not via a small molecule or biologic, but via a targeted electrical signal. Closed loop systems that allow for high bandwidth interfacing of the cortex with the outside world (and vice-versa) will be of significant medical utility, and radically improve patients lives." Dr. Enke Bashllari, Arkitekt Ventures (Series D: $39M) (Recap: $74M) (Series F: $13M) 1. Includes significant funding from DARPA. Note: Paradromics, Inscopix, Wise, Synchron, Kernel and Neuralink represent the six research/platform companies in the set. Sources: PitchBook, CB Insights, SVB analysis Trends in Neuro Device Investing

16 About the Authors Bill provides strategic advice to companies that are creating the next generation of medical technologies. Chris runs the Bay Area & Northwest Digital Health & Medical Device vertical for SVB s Life Science & Healthcare Practice. Kevin heads a team that provides comprehensive financial products and services to medical device and digital health companies. Bill Sideris Senior Associate SVB Securities bsideris@svb.com Chris Moniz Director Silicon Valley Bank cmoniz@svb.com Kevin Longo Northeast Head of Medical Device and Digital Health Silicon Valley Bank klongo@svb.com Contributors Andrew conducts strategic advisory engagements with a focus on biotech mergers and acquisitions. Jon spearheads SVB s strategic relationships with life science and healthcare venture capital firms. Jason manages SVB s loan activity and portfolios for the Medical Device and Digital Health Sectors. Andrew Olson, PhD Manager SVB Securities aolson@svb.com Jonathan Norris Managing Director Silicon Valley Bank jnorris@svb.com Jason Hughes Senior Credit Officer Silicon Valley Bank jhughes@svb.com Trends in Neuro Device Investing

17 About Silicon Valley Bank For more than 35 years, Silicon Valley Bank has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international and private banking services, SVB helps address the unique needs of innovators. This material including, without limitation, the statistical information herein, is provided for informational purposes only. The material is based in part on information from third-party sources that we believe to be reliable but that have not been independently verified by us, and for this reason, we do not represent that the information is accurate or complete. The information should not be viewed as tax, investment, legal or other advice, nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to the material should be construed as a solicitation, offer or recommendation to acquire or dispose of any investment or to engage in any other transaction. Silicon Valley Bank is registered in England and Wales at Alphabeta, Finsbury Square, London EC2A 1BR, UK under No. FC Silicon Valley Bank is authorised and regulated by the California Department of Business Oversight and the United States Federal Reserve Bank; authorised by the Prudential Regulation Authority with number ; and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB). COMPID 1239